INDIVIDUAL TEST 958
Lrp4 Antibodies
Indication
Suspicion of myasthenia gravis (MG)
Sample material
Serum
- Minim. volume: 0,5 mL
Transport
- Within Sweden: room temperature
- International: cold
Method
Cell-based assay (CBA), indirect immunofluorescence(IIF)
Reference interval
Negative
Result
Results are reported as negative, borderline or positive.
Interpretation
Lipoprotein receptor-related protein-4 (LRP4) is a membrane protein in the muscle endplate and forms together with muscle-specific kinase (MuSK) clusters of acetylcholine receptors (AChR).
Antibodies against LRP4 have been reported in 1-5% of patients with myasthenia gravis (MG) patients and can be seen without concomitant antibodies against AChR or MuSK (double negative MG).
When the result is borderline, testing a new sample after 6-12 months is recommended.
References
- Zouvelou V et al. Neuromuscul Disord. 2013. Double seronegative myasthenia gravis with anti-LRP 4 antibodies. PMID: 23768983
- Zisimopoulou P et al. J Autoimmun. 2014. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. PMID: 24373505
- Berrih-Aknin S et al. J Autoimmun. 2014. Diagnostic and clinical classification of autoimmune myasthenia gravis. PMID: 24530233
- Pevzner A et al. J Neurol. 2012. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. PMID: 21814823
- Verschuuren J et al. Neurology. 2021 International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. PMID: 33144515
Last updated: 2025-06-02
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 958
Lrp4-antikroppar
Indikation
Misstanke om myastenia gravis (MG)
Provmaterial
Serum
- Minim. volym: 0,5 mL
Transport
- Inom Sverige: rumstemperatur
- Internationellt: kylt
Metod
Cell-based assay (CBA), indirekt immunofluorescens (IIF)
Referensintervall
Negativt
Resultat
Resultat anges som negativt, gränsvärde eller positivt.
Tolkning
Lipoprotein receptorrelaterat protein-4 (LRP4) är ett membranprotein i muskeländplattan som tillsammans med muskelspecifikt kinas (MuSK) är viktigt för att stabilisera komplex av acetylkolinreceptorer (AChR). Antikroppar mot LRP4 har rapporterats förekomma hos 1–5% av patienter med myastenia gravis (MG) och kan även ses utan samtidig förekomst av antikroppar mot AChR- eller MuSK (dubbelnegativ MG). Vid gränsvärde, rekommenderas att testa ett nytt prov efter 6-12 månader.
Referenser
- Zouvelou V et al. Neuromuscul Disord. 2013. Double seronegative myasthenia gravis with anti-LRP 4 antibodies. PMID: 23768983
- Zisimopoulou P et al. J Autoimmun. 2014. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. PMID: 24373505
- Berrih-Aknin S et al. J Autoimmun. 2014. Diagnostic and clinical classification of autoimmune myasthenia gravis. PMID: 24530233
- Pevzner A et al. J Neurol. 2012. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. PMID: 21814823
- Verschuuren J et al. Neurology. 2021 International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. PMID: 33144515
Senast uppdaterat: 2025-06-02